Drugs / Anti-human Thymoglobulin
Anti-human Thymoglobulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02938741 | Oct 2016 → Dec 2021 | lymphoblastic lymphoma | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-human Thymoglobulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02938741 ↗ |
| Action | Deplete | “by in vivo T cell depletion” NCT02938741 ↗ |
| Modality | Protein / enzyme biologic | “Polyclonal antibodies such as antithymocyte globulins (ATG) have been used for decades.” PMID 17410187 ↗ Apr 2007 |